PIK3CA and breast cancer: PIK3CA mutations have recently reached level 1 evidence for predicting benefit from alpelisib, an alpha-specific PI3K inhibitor, in combination with fulvestrant in patients with advanced HR+/HER2− BC previously treated with endocrine therapy [10].